Consistent with previous studies (Le et al., 2022; Wongvibulsin et al., 2022), both meta-analysis and FAERS analysis showed that anti-CTLA-4 combined with anti-PD/L-1 exhibited a much higher risk than monotherapy for most cutaneous adverse events, such as vitiligo, maculopapular rash, and erythema multiforme. This evidence concerns the gene CTLA4 and vitiligo.